These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 10111796)

  • 1. Evidence and response to the impact of the Medicaid Drug Rebate Program (OBRA) on hospital pharmacy: a progress report from central Ohio.
    Taylor S; Kucukarslan S; Sherrin T
    Hosp Pharm; 1991 Jul; 26(7):621, 624-5. PubMed ID: 10111796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Battered bottom lines: the impact of eroding pharmaceutical discounts on health-care institutions.
    Palumbo FB; Schondelmeyer SW; Miller DW; Speedie SM
    Am J Hosp Pharm; 1992 May; 49(5):1177-85. PubMed ID: 1595750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
    Seay M; Varma P
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules.
    Scott Morton F
    Rand J Econ; 1997; 28(2):269-90. PubMed ID: 11794358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicaid program; time limitation on price recalculations and recordkeeping requirements under the drug rebate program. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Aug; 68(168):51912-7. PubMed ID: 12962118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing prices offered to pharmaceutical purchasing groups.
    Raehtz TR; Milewski R; Massoud N
    Am J Hosp Pharm; 1987 Sep; 44(9):2073-6. PubMed ID: 3674046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Projecting future drug expenditures--1994.
    Santell JP
    Am J Hosp Pharm; 1994 Jan; 51(2):177-87. PubMed ID: 8160668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Summary of 1990 Medicaid drug rebate legislation. ASHP Government Affairs Division.
    Am J Hosp Pharm; 1991 Jan; 48(1):114-7. PubMed ID: 2000867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicaid program; time limitation on recordkeeping requirements under the drug rebate program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2004 Nov; 69(227):68815-8. PubMed ID: 15565749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospital pharmacists' evaluation of drug wholesaler services.
    Allen WO; Ryan MR; Roberts KB
    Am J Hosp Pharm; 1983 Oct; 40(10):1658-61. PubMed ID: 6638028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generics, private-labels may shake stagnant cephalosporin prices.
    Brightbill TC
    Hosp Mater Manage; 1987 Jun; 12(6):3-7. PubMed ID: 10283111
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacy management strategies for responding to hospital reimbursement changes.
    Curtiss FR
    Am J Hosp Pharm; 1983 Sep; 40(9):1489-92. PubMed ID: 6353913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic drug prices fall 7%-24%; groups sort out manufacturers.
    Bernstein T
    Hosp Mater Manage; 1989 Feb; 14(2):8-10. PubMed ID: 10318186
    [No Abstract]   [Full Text] [Related]  

  • 14. Third-party reimbursement for clinical pharmacy services: philosophy and practice.
    Nold EG; Pathak DS
    Am J Hosp Pharm; 1977 Aug; 34(8):823-6. PubMed ID: 900133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABC analysis of the relationship between pharmacy charges and DRGs.
    Magee MJ; Pathak DS; Sherrin TP; Schneider DN
    Am J Hosp Pharm; 1985 Mar; 42(3):571-6. PubMed ID: 3920903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fee for the service of pharmacy: the time has come.
    Tanner DJ
    Hosp Pharm; 1978 Dec; 13(12):692-3, 696. PubMed ID: 10239821
    [No Abstract]   [Full Text] [Related]  

  • 17. Cephalosporin prices rising in wake of Pryor bill.
    Barlow RD
    Hosp Mater Manage; 1991 Jul; 16(7):1, 12-3. PubMed ID: 10112311
    [No Abstract]   [Full Text] [Related]  

  • 18. Implementation of a pharmacy benefit to a managed Medicaid population.
    Smith WW; Perry SC
    Med Interface; 1995 Dec; 8(12):84-7, 97. PubMed ID: 10153524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of drug-procurement alternatives.
    May BE; Herrick JD
    Am J Hosp Pharm; 1984 Jul; 41(7):1373-8. PubMed ID: 6465153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmaceutical industry--prices and progress.
    Scherer FM
    N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.